Preferred Label : quinolones;

MeSH definition : A group of derivatives of naphthyridine carboxylic acid, quinoline carboxylic acid, or NALIDIXIC ACID.;

MeSH synonym : ketoquinolines; oxoquinolines; quinolinones; Ketoquinoline; Quinolone; Oxoquinoline; Quinolinone;

Wikipedia automatic translation : Quinolone antibiotic;

MeSH annotation : do not confuse with QUINOLINES;

Wikipedia link : https://en.wikipedia.org/wiki/Quinolone antibiotic;

Is substance : O;

Details


Main resources

You can consult :

A group of derivatives of naphthyridine carboxylic acid, quinoline carboxylic acid, or NALIDIXIC ACID.

https://www.cbip.be/fr/articles/3762?folia=3757
2022
false
false
false
Belgium
French
journal article
quinolones
anti-bacterial agents
quinolone antibacterials

---
https://www.has-sante.fr/jcms/p_3282752/fr/symkevi-100-mg/150-mg-ivacaftor/-tezacaftor-mucoviscidose-6-ans
2021
false
false
false
France
evaluation of the transparency committee
aminophenols
drug combinations
indoles
quinolones
benzodioxoles
child
adolescent
cystic fibrosis with F508del mutation in the cystic fibrosis transmembrane conductance regulator gene
cystic fibrosis
tezacaftor, ivacaftor drug combination
tezacaftor
ivacaftor
ivacaftor and tezacaftor
drug therapy, combination
treatment outcome
insurance, health, reimbursement
administration, oral

---
https://www.has-sante.fr/jcms/p_3289682/fr/kalydeco-ivacaftor-mucoviscidose-nourrissons-4-6-mois
2021
false
false
false
false
France
treatment outcome
insurance, health, reimbursement
infant
cystic fibrosis
mutation
cystic fibrosis
CFTR Gene
administration, oral
ivacaftor
evaluation of the transparency committee
aminophenols
quinolones
ivacaftor

---
https://www.has-sante.fr/jcms/p_3242947/fr/enerzair-breezhaler
2021
false
false
false
France
insurance, health, reimbursement
treatment outcome
drug combinations
administration, inhalation
indacaterol, glycopyrronium bromide and mometasone
Mometasone Furoate
indacaterol
adrenergic beta-2 receptor agonists
muscarinic antagonists
anti-inflammatory agents
guidelines for drug use
adult
asthma
evaluation of the transparency committee
glycopyrrolate
indans
quinolones

---
https://www.ema.europa.eu/en/medicines/human/EPAR/symkevi
2021
false
false
false
Netherlands
French
English
drug approval
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
drug combinations
tezacaftor, ivacaftor drug combination
tezacaftor
tezacaftor
ivacaftor
ivacaftor
administration, oral
ivacaftor and tezacaftor
Chloride Channel Agonists
Chloride Channel Agonists
cystic fibrosis
drug interactions
pregnancy
breast feeding
child
adolescent
adult
orphan drug production
drug monitoring
cystic fibrosis with F508del mutation in the cystic fibrosis transmembrane conductance regulator gene
aged
drug evaluation, preclinical
aminophenols
indoles
quinolones
benzodioxoles
indoles
benzodioxoles
indoles
benzodioxoles
aminophenols
quinolones
aminophenols
quinolones

---
https://www.ema.europa.eu/en/medicines/human/EPAR/kaftrio
2020
false
false
false
Netherlands
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
Product containing only elexacaftor and ivacaftor and tezacaftor in oral dose form (medicinal product form)
drug approval
europe
drug combinations
administration, oral
orphan drug production
pyrazoles
pyrazoles
pyridines
pyridines
pyrrolidines
pyrrolidines
ivacaftor
ivacaftor
tezacaftor
tezacaftor
adolescent
adult
cystic fibrosis
drug therapy, combination
cystic fibrosis transmembrane conductance regulator
ivacaftor, tezacaftor and elexacaftor
product surveillance, postmarketing
drug interactions
drug evaluation, preclinical
elexacaftor, ivacaftor, tezacaftor drug combination
elexacaftor, ivacaftor, tezacaftor drug combination
elexacaftor
elexacaftor
cystic fibrosis with F508del mutation in the cystic fibrosis transmembrane conductance regulator gene
aminophenols
quinolones
aminophenols
quinolones
indoles
benzodioxoles
indoles
benzodioxoles
quinolines
quinolines

---
https://www.ema.europa.eu/en/medicines/human/EPAR/enerzair-breezhaler
2020
false
false
false
United Kingdom
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
drug approval
europe
drug combinations
indacaterol
indacaterol
indacaterol, glycopyrronium bromide and mometasone
adrenergic beta-2 receptor agonists
adrenergic beta-2 receptor agonists
muscarinic antagonists
muscarinic antagonists
Mometasone Furoate
Mometasone Furoate
administration, inhalation
asthma
adult
anti-inflammatory agents
anti-inflammatory agents
drug interactions
pregnancy
breast feeding
drug evaluation, preclinical
glycopyrrolate
glycopyrrolate
indans
quinolones
indans
quinolones

---
https://www.ema.europa.eu/en/medicines/human/EPAR/atectura-breezhaler
2020
false
false
false
United Kingdom
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
drug approval
europe
drug combinations
indacaterol
indacaterol
adrenergic beta-2 receptor agonists
adrenergic beta-2 receptor agonists
indacaterol and mometasone
mometasone
mometasone
anti-inflammatory agents
anti-inflammatory agents
bronchodilator agents
bronchodilator agents
adult
adolescent
asthma
administration, inhalation
drug interactions
pregnancy
breast feeding
drug evaluation, preclinical
Mometasone Furoate
Mometasone Furoate
indans
quinolones
indans
quinolones

---
https://www.ema.europa.eu/en/medicines/human/EPAR/bemrist-breezhaler
2020
false
false
false
United Kingdom
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
drug approval
europe
drug combinations
administration, inhalation
indacaterol
indacaterol
adrenergic beta-2 receptor agonists
adrenergic beta-2 receptor agonists
bronchodilator agents
bronchodilator agents
mometasone
mometasone
anti-inflammatory agents
anti-inflammatory agents
indacaterol and mometasone
adult
adolescent
asthma
drug interactions
pregnancy
breast feeding
drug evaluation, preclinical
Mometasone Furoate
Mometasone Furoate
indans
quinolones
indans
quinolones

---
https://www.has-sante.fr/jcms/p_3191297/fr/kalydeco
2020
false
false
false
France
ivacaftor
infant
child, preschool
child
treatment outcome
insurance, health, reimbursement
cystic fibrosis
cystic fibrosis transmembrane conductance regulator
mutation
administration, oral
evaluation of the transparency committee
ivacaftor
aminophenols
quinolones
aminophenols
quinolones

---
https://www.has-sante.fr/jcms/p_3184439/fr/symkevi-/-kalydeco
2020
false
false
false
France
drug combinations
administration, oral
insurance, health, reimbursement
ivacaftor and tezacaftor
ivacaftor
cystic fibrosis
adolescent
Product containing only ivacaftor and tezacaftor in oral dose form (medicinal product form)
tezacaftor
CFTR delta F508
treatment outcome
cystic fibrosis with F508del mutation in the cystic fibrosis transmembrane conductance regulator gene
tezacaftor, ivacaftor drug combination
evaluation of the transparency committee
ivacaftor
aminophenols
quinolones
aminophenols
quinolones
indoles
benzodioxoles

---
https://www.ema.europa.eu/en/medicines/human/EPAR/zimbus-breezhaler
2020
false
false
false
United Kingdom
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
drug approval
europe
administration, inhalation
drug combinations
glycopyrrolate
glycopyrrolate
muscarinic antagonists
muscarinic antagonists
indacaterol
indacaterol
adrenergic beta-2 receptor agonists
adrenergic beta-2 receptor agonists
Mometasone Furoate
Mometasone Furoate
anti-inflammatory agents
anti-inflammatory agents
asthma
adult
aged
drug interactions
pregnancy
breast feeding
indacaterol, glycopyrronium bromide and mometasone
drug evaluation, preclinical
indans
quinolones
indans
quinolones

---
https://www.has-sante.fr/jcms/p_3220388/fr/kaftrio-/-kalydeco
2020
false
false
false
France
drug combinations
treatment outcome
insurance, health, reimbursement
ivacaftor
Chloride Channel Agonists
tezacaftor
ivacaftor
ivacaftor, tezacaftor and elexacaftor
cystic fibrosis
adolescent
adult
CFTR delta F508
cystic fibrosis transmembrane conductance regulator delta F508
administration, oral
elexacaftor
elexacaftor, ivacaftor, tezacaftor drug combination
evaluation of the transparency committee
aminophenols
quinolones
indoles
benzodioxoles
cystic fibrosis transmembrane conductance regulator
pyrrolidines
pyridines
pyrazoles
drug combinations
quinolines

---
https://www.inesss.qc.ca/thematiques/medicaments/medicaments-evaluation-aux-fins-dinscription/extrait-davis-au-ministre/atectura-breezhaler-5427.html
2020
false
false
false
Canada
French
drug evaluation
indacaterol and mometasone
drug combinations
administration, inhalation
asthma
indacaterol
Mometasone Furoate
indans
quinolones

---
https://www.inesss.qc.ca/thematiques/medicaments/medicaments-evaluation-aux-fins-dinscription/extrait-davis-au-ministre/enerzair-breezhaler-5428.html
2020
false
false
false
Canada
French
asthma
drug combinations
administration, inhalation
drug evaluation
Mometasone Furoate
indacaterol
indacaterol, glycopyrronium bromide and mometasone
glycopyrrolate
indans
quinolones

---
https://www.has-sante.fr/jcms/p_3224934/fr/quofenix
2020
false
false
false
France
French
evaluation of the transparency committee
insurance, health, reimbursement
treatment outcome
delafloxacin
delafloxacin
anti-bacterial agents
acute disease
soft tissue infections
skin diseases, bacterial
Methicillin-Resistant staphylococcus aureus
staphylococcal infections
Methicillin resistant Staphylococcus aureus infection (disorder)
administration, oral
infusions, intravenous
quinolones
fluoroquinolones

---
https://www.has-sante.fr/jcms/p_3215558/fr/enerzair-breezhaler
2020
false
false
false
France
treatment outcome
insurance, health, reimbursement
drug combinations
administration, inhalation
Mometasone Furoate
indacaterol
adrenergic beta-2 receptor agonists
muscarinic antagonists
anti-inflammatory agents
indacaterol, glycopyrronium bromide and mometasone
asthma
adult
bronchodilator agents
evaluation of the transparency committee
glycopyrrolate
indans
quinolones

---
https://ansm.sante.fr/informations-de-securite/antibiotiques-de-la-famille-des-quinolones-et-fluoroquinolones-administres-par-voie-systemique-ou-inhalee-risque-deffets-indesirables-invalidants-durables-et-potentiellement-irreversibles-et-restrictions-dutilisation
2019
false
false
false
France
French
anti-bacterial agents
administration, oral
administration, inhalation
infusions, intravenous
pharmacovigilance note
guidelines for drug use
quinolone antibacterials
Safety-Based drug withdrawals
Tendon rupture
tendinopathy
fluoroquinolones
Contraindications, Drug
ciprofloxacin
levofloxacin
lomefloxacin
Moxifloxacin
norfloxacin
flumequine
ofloxacin
quinolones
joint diseases
muscular diseases
nervous system diseases

---
https://www.ema.europa.eu/en/medicines/human/EPAR/quofenix
2019
false
false
false
United Kingdom
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
drug approval
europe
delafloxacin
delafloxacin
anti-bacterial agents
anti-bacterial agents
delafloxacin
adult
skin diseases, bacterial
infusions, intravenous
administration, oral
product surveillance, postmarketing
soft tissue infections
acute disease
aged
drug interactions
pregnancy
breast feeding
topoisomerase II inhibitors
DNA topoisomerase IV
drug evaluation, preclinical
quinolones
fluoroquinolones
quinolones
fluoroquinolones

---
https://www.has-sante.fr/jcms/p_3109937/fr/orkambi
2019
false
false
false
France
ivacaftor
lumacaftor
administration, oral
treatment outcome
insurance, health, reimbursement
child
cystic fibrosis
cystic fibrosis transmembrane conductance regulator delta F508
mutation
ivacaftor and lumacaftor
evaluation of the transparency committee
lumacaftor, ivacaftor drug combination
drug combinations
quinolones
benzodioxoles
aminophenols
aminopyridines
cystic fibrosis transmembrane conductance regulator

---
https://www.has-sante.fr/jcms/p_3098921/fr/kalydeco
2019
false
false
false
France
administration, oral
infant
child
cystic fibrosis
ivacaftor
ivacaftor
treatment outcome
insurance, health, reimbursement
evaluation of the transparency committee
aminophenols
quinolones

---
https://ansm.sante.fr/informations-de-securite/genvoya-r-stribild-r-risque-accru-dechec-virologique-et-secondairement-de-transmission-de-linfection-vih-de-la-mere-a-lenfant
2019
false
false
false
France
French
infectious disease transmission, vertical
treatment failure
hiv infections
pregnancy trimester, second
pregnancy trimester, third
hiv infections
pharmacovigilance note
anti-hiv agents
elvitegravir
Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination
guidelines for drug use
risk
emtricitabine, tenofovir alafenamide, elvitegravir and cobicistat
emtricitabine, tenofovir disoproxil, elvitegravir and cobicistat
pregnancy
infant, newborn
elvitegravir
Emtricitabine
Tenofovir
Cobicistat
drug combinations
quinolones
quinolones

---
https://www.inesss.qc.ca/index.php?id=72&DemandePluginController%5Buid%5D=4433&DemandePluginController%5Bonglet%5D=2&DemandePluginController%5BbackUrl%5D=%252Findex.php%253Fid%253D72%2526no_cache%253D1%2526DemandePluginController%25255Buid%25255D%253D4535%2526DemandePluginController%25255Bonglet%25255D%253D2%2526DemandePluginController%25255BbackUrl%25255D%253D%2525252Findex.php%2525253Fid%2525253D72%25252526no_cache%2525253D1%25252526DemandePluginController%252525255Buid%252525255D%2525253D4526%25252526DemandePluginController%252525255Bonglet%252525255D%2525253D2%25252526DemandePluginController%252525255BbackUrl%252525255D%2525253D%25252525252Findex.php%25252525253Fid%25252525253D72%252525252526no_cache%25252525253D1%252525252526DemandePluginController%2525252525255Buid%2525252525255D%25252525253D4469%252525252526DemandePluginController%2525252525255Bonglet%2525252525255D%25252525253D2%252525252526DemandePluginController%2525252525255BbackUrl%2525252525255D%25252525253D%252525252525252Findex.php%252525252525253Fid%252525252525253D72%2525252525252526no_cache%252525252525253D1%2525252525252526DemandePluginController%25252525252525255Buid%25252525252525255D%252525252525253D4496%2525252525252526DemandePluginController%25252525252525255Bonglet%25252525252525255D%252525252525253D2&cHash=a44ffc75b859ef1167959ab5debed264
2018
false
false
false
Canada
French
drug evaluation
canada
ozenoxacin
aminopyridines
quinolones

---
https://www.ema.europa.eu/en/medicines/human/EPAR/rxulti
2018
false
false
false
United Kingdom
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
brexpiprazole
brexpiprazole
drug approval
europe
schizophrenia
adult
administration, oral
product surveillance, postmarketing
drug interactions
pregnancy
breast feeding
antipsychotic agents
antipsychotic agents
drug evaluation, preclinical
thiophenes
quinolones
thiophenes
quinolones

---
https://hpr-rps.hres.ca/reg-content/sommaire-motif-decision-detailTwo.php?lang=fr&linkID=SBD00402
2018
false
false
false
Canada
French
drug information
administration, oral
drug approval
canada
ivacaftor and tezacaftor
drug combinations
tezacaftor
tezacaftor
ivacaftor
ivacaftor
cystic fibrosis
adolescent
adult
cystic fibrosis
cystic fibrosis transmembrane conductance regulator
mutation
treatment outcome
indoles
benzodioxoles
indoles
benzodioxoles
aminophenols
quinolones
aminophenols
quinolones
tezacaftor, ivacaftor drug combination

---
https://www.has-sante.fr/portail/jcms/c_2889886/fr/orkambi
https://www.has-sante.fr/portail/jcms/c_2889886/fr/orkambi-lumacaftor-/-ivacaftor-correcteur-et-potentialisateur-du-gene-cftr
2018
false
false
false
France
French
drug combinations
aminophenols
aminopyridines
aminopyridines
aminophenols
quinolones
quinolones
benzodioxoles
benzodioxoles
adolescent
adult
CFTR gene.p.F508 del
cystic fibrosis transmembrane conductance regulator
cystic fibrosis transmembrane conductance regulator delta F508
cystic fibrosis
ivacaftor
ivacaftor
treatment outcome
ivacaftor and lumacaftor
lumacaftor, ivacaftor drug combination
lumacaftor, ivacaftor drug combination
evaluation of the transparency committee
insurance, health, reimbursement
forced expiratory volume
orphan drug production
guidelines for drug use
lumacaftor
lumacaftor
cystic fibrosis transmembrane conductance regulator

---
Summary Basis of Decision (SBD) for Ozanex
Ozenoxacin cream 1% w/w, topical
https://hpr-rps.hres.ca/reg-content/sommaire-motif-decision-detailTwo.php?lang=fr&linkID=SBD00358
2017
false
false
false
Canada
French
drug information
ozenoxacin
administration, cutaneous
drug approval
canada
treatment outcome
ozenoxacin
anti-bacterial agents
anti-bacterial agents
impetigo
infant
child
adolescent
adult
ozenoxacin
ointments
aminopyridines
quinolones
aminopyridines
quinolones

---
Summary Basis of Decision (SBD) for Rexulti
Brexpiprazole 0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg and 4 mg tablets, oral
https://hpr-rps.hres.ca/reg-content/sommaire-motif-decision-detailTwo.php?lang=fr&linkID=SBD00353
2017
false
false
false
Canada
French
drug information
brexpiprazole
brexpiprazole
drug approval
canada
treatment outcome
schizophrenia
antipsychotic agents
adult
aged
brexpiprazole
antipsychotic agents
tablets
administration, oral
thiophenes
quinolones
thiophenes
quinolones

---
http://www.has-sante.fr/portail/jcms/c_2656337/fr/orkambi
http://www.has-sante.fr/portail/jcms/c_2656337/fr/orkambi-lumacaftor-/-ivacaftor-correcteur-et-potentialisateur-du-gene-cftr
2016
false
false
false
France
French
drug combinations
aminophenols
aminopyridines
aminopyridines
aminophenols
quinolones
quinolones
benzodioxoles
benzodioxoles
adolescent
adult
CFTR gene.p.F508 del
cystic fibrosis transmembrane conductance regulator
cystic fibrosis transmembrane conductance regulator delta F508
cystic fibrosis
ivacaftor
ivacaftor
treatment outcome
ivacaftor and lumacaftor
lumacaftor, ivacaftor drug combination
lumacaftor, ivacaftor drug combination
evaluation of the transparency committee
insurance, health, reimbursement
forced expiratory volume
guidelines for drug use
orphan drug production
lumacaftor
lumacaftor
cystic fibrosis transmembrane conductance regulator
drug combinations
drug combinations

---
http://www.has-sante.fr/portail/jcms/c_2621468/fr/genvoya
http://www.has-sante.fr/portail/jcms/c_2621468/fr/genvoya-emtricitabine-cobicistat-elvitegravir-et-tenofovir-alafenamide-association-d-antiviraux
2016
false
false
false
France
French
treatment outcome
drug combinations
tenofovir alafenamide
elvitegravir
hiv infections
anti-hiv agents
adult
adolescent
human immunodeficiency virus i infection
administration, oral
HIV integrase inhibitors
reverse transcriptase inhibitors
emtricitabine, tenofovir alafenamide, elvitegravir and cobicistat
Cobicistat
Emtricitabine
evaluation of the transparency committee
guidelines for drug use
tenofovir alafenamide
elvitegravir
adenine
adenine
quinolones

---
https://www.minerva-ebp.be/fr/article/1054
2015
false
false
false
minerva-ebm.be
Belgium
French
critical appraisal or critical reading
pulmonary disease, chronic obstructive
drug therapy, combination
treatment outcome
indacaterol
glycopyrrolate
muscarinic antagonists
bronchodilator agents
indacaterol-glycopyrronium combination
Tiotropium Bromide
indans
quinolones
glycopyrrolate

---
http://www.cochrane.org/fr/CD010139/lindacaterol-pour-le-traitement-de-personnes-atteintes-de-bpco-stable
2015
false
false
false
France
United Kingdom
French
review of literature
treatment outcome
pulmonary disease, chronic obstructive
indacaterol
adrenergic beta-2 receptor agonists
administration, inhalation
dose-response relationship, drug
drug administration schedule
french abstract
indans
quinolones

---
https://www.minerva-ebp.be/FR/Analysis/424
2015
false
true
false
Belgium
French
french abstract
scientific and technical information
adrenergic beta-agonists
treatment outcome
placebos
pulmonary disease, chronic obstructive
indacaterol
indans
quinolones

---
https://www.ema.europa.eu/medicines/human/EPAR/Genvoya
2015
false
false
false
United Kingdom
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
drug combinations
drug approval
europe
tenofovir alafenamide
tenofovir alafenamide
elvitegravir
elvitegravir
hiv infections
drug interactions
pregnancy
breast feeding
product surveillance, postmarketing
drug evaluation, preclinical
anti-hiv agents
anti-hiv agents
adult
adolescent
human immunodeficiency virus i infection
administration, oral
Substance with integrase strand transfer inhibitor mechanism of action (substance)
HIV integrase inhibitors
HIV integrase inhibitors
Cytochrome P-450 CYP3A Inhibitors
Cytochrome P-450 CYP3A Inhibitors
reverse transcriptase inhibitors
reverse transcriptase inhibitors
emtricitabine, tenofovir alafenamide, elvitegravir and cobicistat
Cobicistat
Cobicistat
Emtricitabine
Emtricitabine
tenofovir alafenamide
tenofovir alafenamide
elvitegravir
elvitegravir
adenine
adenine
adenine
quinolones
quinolones

---
https://www.ema.europa.eu/medicines/human/EPAR/Orkambi
2015
false
false
false
United Kingdom
French
English
summary of product characteristics
package leaflet
drug combinations
aminophenols
aminopyridines
aminopyridines
aminophenols
quinolones
quinolones
benzodioxoles
benzodioxoles
continuity of patient care
adolescent
adult
CFTR gene.p.F508 del
cystic fibrosis transmembrane conductance regulator
cystic fibrosis transmembrane conductance regulator delta F508
cystic fibrosis
ivacaftor
ivacaftor
drug evaluation
syndication feed
drug approval
europe
treatment outcome
pregnancy
breast feeding
drug interactions
drug evaluation, preclinical
product surveillance, postmarketing
ivacaftor and lumacaftor
lumacaftor, ivacaftor drug combination
lumacaftor, ivacaftor drug combination
lumacaftor
lumacaftor
cystic fibrosis transmembrane conductance regulator
drug combinations
drug combinations

---
http://www.pharmactuel.com/index.php/pharmactuel/article/view/1010
2015
false
false
false
false
Canada
French
drug combinations
administration, inhalation
indacaterol-glycopyrronium combination
indacaterol
critical appraisal or critical reading
glycopyrrolate
cholinergic antagonists
adrenergic beta-2 receptor agonists
pulmonary disease, chronic obstructive
bronchodilator agents
treatment outcome
multicenter studies as topic
COPD exacerbation
disease exacerbation
indacaterol and glycopyrronium bromide
quality of life
disease progression
indans
quinolones
glycopyrrolate

---
http://base-donnees-publique.medicaments.gouv.fr/extrait.php?specid=65036318
2014
summary of product characteristics
dandruff
dandruff
ivacaftor
tablets
aminophenols
ivacaftor
quinolones

---
http://www.has-sante.fr/portail/jcms/c_1744044/fr/ultibro-breezhaler-indacaterol-glycopyrronium-bronchodilatateur
2014
false
France
French
indacaterol and glycopyrronium bromide
evaluation of the transparency committee
Indacaterol Maleate
insurance, health, reimbursement
treatment outcome
bronchodilator agents
guidelines for drug use
indacaterol
glycopyrrolate
drug combinations
administration, inhalation
muscarinic antagonists
adrenergic beta-2 receptor agonists
pulmonary disease, chronic obstructive
adult
indans
quinolones

---
http://medicalforum.ch/fr/n-actuel/article/ivacaftor-le-premier-medicament-pour-le-traitement-causal-de-la-mucoviscidose.html
https://medicalforum.ch/fr/detail/doi/fms.2014.02076/
2014
false
false
false
Switzerland
French
journal article
case reports
cystic fibrosis
child
ivacaftor
aminophenols
quinolones
cystic fibrosis
mutation
treatment outcome

---
http://www.cochrane.org/fr/CD010475
2013
United Kingdom
France
French
laquinimod
review of literature
multiple sclerosis
treatment outcome
french abstract
quinolones
quinolones
laquinimod
laquinimod

---
https://hpr-rps.hres.ca/reg-content/sommaire-motif-decision-detailOne.php?lang=fr&linkID=SBD00106
2012
false
false
false
Canada
Indacaterol 75microgram inhalation powder capsule (product)
indacaterol
indacaterol
drug information
indans
quinolones

---
https://www.jle.com/fr/revues/medecine/met/e-docs/00/04/72/65/resume.phtml
2011
France
French
drug resistance, bacterial
quinolones
escherichia coli infections
review of literature

---
http://www.cochrane.org/fr/CD003597
2010
false
true
false
France
United Kingdom
female
treatment outcome
review of literature
french abstract
quinolones
cystitis

---
Nous contacter.
20/05/2024


[Home] [Top]

© Rouen University Hospital. Any partial or total use of this material must mention the source.